Natco Pharma concludes FDA inspection at Hyderabad plant

Natco Pharma Limited (BSE: 524816, NSE: NATCOPHARM) today announced the completion of a U.S. Food and Drug Administration (FDA) inspection at its Active Pharmaceutical Ingredients (API) manufacturing facility located in Mekaguda, Hyderabad, India. The inspection, which took place from June 9th to June 13th, 2025, resulted in one observation on Form 483, which the company believes is procedural in nature. Natco Pharma is confident that it can comprehensively address the observation and remains committed to maintaining cGMP compliance and delivering high-quality products to its customers worldwide.